Natasha Rekhtman

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. doi request reprint Neuroendocrine tumors of the lung: an update
    Natasha Rekhtman
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Arch Pathol Lab Med 134:1628-38. 2010
  2. pmc Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-Small Cell Carcinoma-like Subsets
    Natasha Rekhtman
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York
    Clin Cancer Res 22:3618-29. 2016
  3. pmc Distinct profile of driver mutations and clinical features in immunomarker-defined subsets of pulmonary large-cell carcinoma
    Natasha Rekhtman
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Mod Pathol 26:511-22. 2013
  4. pmc Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations
    Natasha Rekhtman
    Department of Pathology, Thoracic Oncology Service, Department of Medicine, and Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, NY 10065, USA
    Clin Cancer Res 18:1167-76. 2012
  5. doi request reprint Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing
    Natasha Rekhtman
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York City, New York 10065, USA
    J Thorac Oncol 6:451-8. 2011
  6. doi request reprint Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens
    Natasha Rekhtman
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Mod Pathol 24:1348-59. 2011
  7. pmc Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers
    Helena A Yu
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Clin Cancer Res 19:2240-7. 2013
  8. doi request reprint Subtyping of non-small cell lung carcinoma: a comparison of small biopsy and cytology specimens
    Carlie S Sigel
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York City, New York 10065, USA
    J Thorac Oncol 6:1849-56. 2011
  9. pmc KRAS mutations are associated with solid growth pattern and tumor-infiltrating leukocytes in lung adenocarcinoma
    Natasha Rekhtman
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Mod Pathol 26:1307-19. 2013
  10. pmc EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics
    Maria E Arcila
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Mol Cancer Ther 12:220-9. 2013

Collaborators

Detail Information

Publications30

  1. doi request reprint Neuroendocrine tumors of the lung: an update
    Natasha Rekhtman
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Arch Pathol Lab Med 134:1628-38. 2010
    ..Markedly different prognostic implications and treatment paradigms for these tumors underscore the importance of accurate pathologic diagnosis...
  2. pmc Next-Generation Sequencing of Pulmonary Large Cell Neuroendocrine Carcinoma Reveals Small Cell Carcinoma-like and Non-Small Cell Carcinoma-like Subsets
    Natasha Rekhtman
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York
    Clin Cancer Res 22:3618-29. 2016
    ..To clarify these relationships, we analyzed genomic alterations in LCNEC compared with other major lung carcinoma types...
  3. pmc Distinct profile of driver mutations and clinical features in immunomarker-defined subsets of pulmonary large-cell carcinoma
    Natasha Rekhtman
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Mod Pathol 26:511-22. 2013
    ..These findings have practical implications for diagnosis, predictive molecular testing and therapy selection...
  4. pmc Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations
    Natasha Rekhtman
    Department of Pathology, Thoracic Oncology Service, Department of Medicine, and Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, NY 10065, USA
    Clin Cancer Res 18:1167-76. 2012
    ....
  5. doi request reprint Suitability of thoracic cytology for new therapeutic paradigms in non-small cell lung carcinoma: high accuracy of tumor subtyping and feasibility of EGFR and KRAS molecular testing
    Natasha Rekhtman
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York City, New York 10065, USA
    J Thorac Oncol 6:451-8. 2011
    ..The aim of this study was to comprehensively review the performance of cytologic specimens for the above two goals in a high-volume clinical practice...
  6. doi request reprint Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens
    Natasha Rekhtman
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Mod Pathol 24:1348-59. 2011
    ..This simple algorithm achieves excellent accuracy in small specimens while conserving the tissue for potential predictive marker testing, which is now an essential consideration in advanced lung cancer specimens...
  7. pmc Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers
    Helena A Yu
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Clin Cancer Res 19:2240-7. 2013
    ..Smaller series have identified various mechanisms of resistance, but systematic evaluation of a large number of patients to definitively establish the frequency of various mechanisms has not been conducted...
  8. doi request reprint Subtyping of non-small cell lung carcinoma: a comparison of small biopsy and cytology specimens
    Carlie S Sigel
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York City, New York 10065, USA
    J Thorac Oncol 6:1849-56. 2011
    ..The relative feasibility and accuracy of NSCLC subtyping by small biopsy versus cytology is not well established, particularly in current practice where immunohistochemistry (IHC) is becoming routinely used to aid in this distinction...
  9. pmc KRAS mutations are associated with solid growth pattern and tumor-infiltrating leukocytes in lung adenocarcinoma
    Natasha Rekhtman
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Mod Pathol 26:1307-19. 2013
    ..Solid growth pattern was recently shown to be a strong predictor of aggressive behavior in lung adenocarcinomas, which may underlie the unfavorable prognosis associated with KRAS mutations in these tumors. ..
  10. pmc EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics
    Maria E Arcila
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Mol Cancer Ther 12:220-9. 2013
    ..Insertions are structurally heterogeneous with potential implications for response to EGFR inhibitors...
  11. doi request reprint Predicting pulmonary adenocarcinoma outcome based on a cytology grading system
    Carlie S Sigel
    1Memorial Sloan Kettering Cancer Center, Department of Pathology, New York, New York, USA
    Cancer Cytopathol 120:35-43. 2012
    ..Therefore, we evaluated cytomorphologic features of previously histologically graded AD to identify features of potential prognostic significance...
  12. pmc Small-cell lung cancers in patients who never smoked cigarettes
    Anna M Varghese
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center Department of Medicine, Weill Cornell Medical College Department of Pathology and Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY
    J Thorac Oncol 9:892-6. 2014
    ..We describe clinical, pathologic, and molecular characteristics of never-smoker patients with small-cell lung cancers (SCLCs)...
  13. doi request reprint Use of touch imprint cytology as a simple method to enrich tumor cells for molecular analysis
    Snjezana Dogan
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Cancer Cytopathol 121:354-60. 2013
    ....
  14. pmc Next-Generation Sequencing of Stage IV Squamous Cell Lung Cancers Reveals an Association of PI3K Aberrations and Evidence of Clonal Heterogeneity in Patients with Brain Metastases
    Paul K Paik
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York Weill Cornell Medical College, New York, New York
    Cancer Discov 5:610-21. 2015
    ..SQCLC primaries that gave rise to brain metastases exhibited truncal PTEN loss. SQCLC brain metastases exhibited a high degree of genetic heterogeneity and evidence of clonal differences between their primary sites...
  15. pmc Using frozen section to identify histological patterns in stage I lung adenocarcinoma of ≤ 3 cm: accuracy and interobserver agreement
    Yi Chen Yeh
    Division of Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Histopathology 66:922-38. 2015
    ..The aim of this study was to investigate the accuracy, limitations and interobserver agreement of frozen sections for predicting histological subtype...
  16. pmc Phase II study of docetaxel and vinorelbine as adjuvant chemotherapy for resected non-small cell lung cancers
    Jamie E Chaft
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, 300 E, 66th Street, New York, NY, 10065, USA
    Cancer Chemother Pharmacol 72:931-4. 2013
    ..For cisplatin ineligible patients, there is no standard adjuvant option. We evaluated drug delivery and toxicity of docetaxel and vinorelbine in patients who could not receive cisplatin...
  17. pmc Response to erlotinib in patients with EGFR mutant advanced non-small cell lung cancers with a squamous or squamous-like component
    Paul K Paik
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, 300 East 66 Street, New York, NY 10065, USA
    Mol Cancer Ther 11:2535-40. 2012
    ..These tumors can mimic SCC in small samples. We propose an approach to increase the capture of these rare histology patients for EGFR mutation testing...
  18. doi request reprint Cribriform and fused glands are patterns of high-grade pulmonary adenocarcinoma
    Andre L Moreira
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA Electronic address
    Hum Pathol 45:213-20. 2014
    ..932) and was significantly worse than that for low- and intermediate-grade tumors (P = .0025). Complex glandular patterns have a significant prognostic value and should be considered patterns of high-grade adenocarcinoma. ..
  19. doi request reprint Progenitor stem cell marker expression by pulmonary carcinomas
    Andre L Moreira
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Mod Pathol 23:889-95. 2010
    ..Therefore, stem cell markers are expressed in lung cancers with different patterns seen for different histological types and degrees of differentiation...
  20. doi request reprint Squamous-cell carcinomas of the lung: emerging biology, controversies, and the promise of targeted therapy
    Alexander Drilon
    Department of Medicine Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Lancet Oncol 13:e418-26. 2012
    ....
  21. doi request reprint Pathological diagnosis and classification of lung cancer in small biopsies and cytology: strategic management of tissue for molecular testing
    William D Travis
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Semin Respir Crit Care Med 32:22-31. 2011
    ..The need for every institution to develop a multidisciplinary strategy to obtain these small specimens and process them not only for diagnosis but also for molecular testing is emphasized...
  22. doi request reprint Spread through Air Spaces (STAS) Is an Independent Predictor of Recurrence and Lung Cancer-Specific Death in Squamous Cell Carcinoma
    Shaohua Lu
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York Thoracic Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, People s Republic of China
    J Thorac Oncol . 2016
    ..Spread through air spaces (STAS) is a recently recognized pattern of invasion in lung adenocarcinoma; however, it has not yet been characterized in squamous cell carcinoma (SCC)...
  23. pmc Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping
    Paul K Paik
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York Weill Cornell Medical College, New York, New York
    Cancer Discov 5:842-9. 2015
    ....
  24. pmc Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial
    Alexander Drilon
    Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medicine, New York, NY, USA Electronic address
    Lancet Oncol 17:1653-1660. 2016
    ..To assess the activity of cabozantinib in patients with RET-rearranged lung cancers, we did a prospective phase 2 trial in this molecular subgroup...
  25. pmc Cytology assessment can predict survival for patients with metastatic pancreatic neuroendocrine neoplasms
    Carlie S Sigel
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York
    Cancer . 2017
    ..In the current study, the authors evaluated concordance for grade and differentiation between concurrent core needle biopsy and cytology preparations. Cytological features and grade then were correlated with survival...
  26. pmc Advances in fine needle aspiration cytology for the diagnosis of pulmonary carcinoma
    Adnan Hasanovic
    Department of Pathology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
    Patholog Res Int 2011:897292. 2011
    ..In this paper we will review the current concepts in the suitability and accuracy of fine needle aspiration biopsy, including diagnosis, classification, prognostic markers, and use of ancillary techniques...
  27. doi request reprint Malignant solitary fibrous tumor: cytopathologic findings and differential diagnosis
    Justin A Bishop
    Department of Pathology, Johns Hopkins Hospital, 600 North Wolfe Street, Baltimore, MD 21287, USA
    Cancer Cytopathol 118:83-9. 2010
    ..Malignant solitary fibrous tumors (SFTs) are extremely uncommon and poorly understood mesenchymal neoplasms. There are only rare published accounts of the cytopathologic features of these tumors, prompting the current study...
  28. pmc Morphologic Accuracy in Differentiating Primary Lung Adenocarcinoma From Squamous Cell Carcinoma in Cytology Specimens
    Maureen F Zakowski
    From the Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York Drs Zakowski and Rekhtman the Department of Pathology, Royal Victoria Hospital, Montreal, Quebec, Canada Dr Auger the Department of Pathology, Cleveland Clinic Main Campus, Cleveland, Ohio Dr Booth the Department of Pathology, Walter Reed Army Medical Center, Washington, DC Dr Crothers the Department of Pathology, Peacehealth Laboratory, Vancouver, Washington Dr Ghofrani the Department of Pathology, University of Pittsburgh Medical Center Shadyside, Pittsburgh, Pennsylvania Dr Khalbuss the Department of Pathology, Baylor College of Medicine, Houston, Texas Dr Laucirica the Department of Pathology, AmeriPath, Indianapolis, Indiana Dr Moriarty the Department of Pathology, University of California, San Francisco Dr Tabatabai and the Department of Pathology, Loyola University Medical Center, Maywood, Illinois Dr Barkan Dr Zakowski is no longer affiliated with Memorial Sloan Kettering Cancer Center Dr Khalbuss is now with GE Clarient Diagnostic Services, Riyadh, Saudi Arabia Dr Moriarty is no longer affiliated with AmeriPath
    Arch Pathol Lab Med 140:1116-20. 2016
    ..As the majority of patients present at a later stage, the subclassification and molecular analysis must be done on cytologic material...
  29. pmc Reevaluation and reclassification of resected lung carcinomas originally diagnosed as squamous cell carcinoma using immunohistochemical analysis
    Kyuichi Kadota
    Thoracic Service, Department of Surgery Department of Pathology Center for Cell Engineering, Memorial Sloan Kettering Cancer Center, New York, NY Department of Diagnostic Pathology, Faculty of Medicine, Kagawa University, Kagawa Department of Thoracic Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
    Am J Surg Pathol 39:1170-80. 2015
    ..Our findings suggest that TTF-1 8G7G3/1 may be better suited as the primary antibody in differentiating adenocarcinoma from squamous cell carcinoma. ..
  30. ncbi request reprint A 62-year-old woman with a suspected thyroid nodule
    Natasha Rekhtman
    Department of Pathology, The Johns Hopkins Hospital, Baltimore, MD 21287, USA
    Arch Pathol Lab Med 129:1497-8. 2005